SFA Therapeutics is currently conducting a Phase 1b clinical trial (NCT05642182) evaluating SFA-002 in patients with mild-to-moderate plaque psoriasis.  This open-label prospective study is examining two different formulations across two cohorts, with a treatment protocol consisting of 12 weeks of active therapy, followed by one month of follow-up and an optional 12-week extension period.

​

​​

CURRENT RESULTS

​

Cohort 2 showed a stronger response and is the formulation advancing into Phase 2.

​

​

​

​

​

​

​

​

​

​

​

​​

​

​

​

​

​

​​

Most notably, the safety profile has been excellent.

​

     NO treatment-related adverse events were observed.

​

     NO toxicities during the treatment period and follow-up were observed.

​

     NO rebound effects after treatment completion were observed .

​

​

​​​​

MOVING FORWARD

​

SFA Therapeutics will investigate evidence of durable effect seen after longer treatment.

​

​

​

​​